antiplatelet drugs

PreclinicalSmall molecule

Bayer

antiplatelet drugs is one of 7 small molecule programs targeting Head Injury. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head InjuryActive, not recruiting

Head InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Head Injury

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Epsom Salt

FFresenius Kabi USA, LLC

Cortrosyn

1 4

Depakote

Teva

Preclinical

1 5

Direct Anticoagulant

Bayer

Preclinical

1 6

Metopirone

TTerezinha de Jesus Esteves Barata

Preclinical

1 7

antiplatelet drugs

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rivaroxaban1 trial

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Completed· Bayer logo

Bayer··NCT01947998·50,299 enrolled

Head Injury1 trial

Mild Head Injury, Antiplatelets, and Anticoagulants

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT04741334·2,127 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for antiplatelet drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — antiplatelet drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for antiplatelet drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

antiplatelet drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rivaroxaban1 trial

Head Injury1 trial

References

Drug Info

Quick Facts

Related News